Latest
By Staff Report / Monday, December 7th, 2015 / Central Coast Health Watch, Latest news, Tri-County Public Companies / Comments Off on Novartis biosimilar works as well as Amgen’s Neulasta
Swiss pharmaceutical Novartis announced Monday that a copycat version of Amgen’s Neulasta works just as well to prevent a condition that can lead to infection in women with breast cancer. Neulasta stimulates white blood cell production in the body, which helps the body fight cancer. Novartis’ new drug is part of a new class of Read More →
Read More →
Latest
By Philip Joens / Friday, December 4th, 2015 / Central Coast Health Watch, East Ventura County, Latest news, Tri-County Public Companies / Comments Off on Amgen seeks European OK of biosimilar drug, partners with Merck on studies
Amgen announced two developments Dec. 4 that should help the Thousand Oaks-based biotech giant compete. Amgen said it is seeking approval from the European Medicines Agency for ABP 501, a biosimilar drug similar to Humira. Amgen also announced a partnership with New Jersey-based pharmaceutical Merck to partner in a non-Hodgkins lymphoma study using drugs from Read More →
Read More →
Latest
By Philip Joens / Friday, November 27th, 2015 / Central Coast Health Watch, Latest news, Top Stories / Comments Off on Diabetes drug may be game changer
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Read More →
Latest
By Staff Report / Wednesday, November 25th, 2015 / Central Coast Health Watch, Latest news, Top Stories / Comments Off on Amgen asks FDA to approve biosimilar drug
Amgen submitted an application to the Food and Drug Administration for approval of its biosimilar drug ABP 501 on Nov. 25. ABP 501 is designed as a lower-cost version of Humira, which is approved to treat nine conditions including arthritis, skin disorders and colon inflammation. Humira, made by Chicago-based AbbVie, typically costs $20,000 per year Read More →
Read More →
Latest
By Henry Dubroff / Friday, November 20th, 2015 / Central Coast Health Watch, Columns, Latest news / Comments Off on Dignity Health investment in Central Coast paying off
During the past five years, Dignity Health has made methodical moves to bolster the healthcare system in North Santa Barbara and San Luis Obispo counties. That strategy has paid off in improved patient care and better facilities. Now health care is emerging as an industry that attracts talent and capital. It’s an industry that has Read More →
Read More →